A set of emerging diagnostic tools may help identify breast cancer patients who are most likely to benefit from therapies that target important enzymes fueling a range of subtypes, including BCRA-mutated and triple negative ...
Dec 6, 2018
0
3
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ways to wake up the immune system so it recognizes and attacks invading cancer cells. Tumors protect themselves by tricking the immune system into ...
Jul 25, 2014
0
0
One major hallmark of cancer cells is their ability to survive under stressful conditions. A new study spearheaded by researchers at Sanford-Burnham Medical Research Institute reveals how a promising anticancer compound called ...
Jul 30, 2013
0
0
(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology.
Mar 1, 2019
0
2
Researchers have gained a better understanding of the complexity of the environment in which T cells thrive and, by extension, the tolerance mechanisms of these cells which are an obstacle to cellular immunity.
Sep 17, 2020
0
47
For more than a decade, oncologists using cytotoxic chemotherapy to treat patients with advanced metastatic castration-resistant prostate cancer (mCRPC) have relied on the sequential use of single agent taxanes such as docetaxel ...
May 31, 2015
0
17
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow.
May 28, 2013
0
0
Columbia University Medical Center (CUMC) researchers are developing a new approach to cancer clinical trials, in which therapies are designed and tested one patient at a time. The patient's tumor is "reverse engineered" ...
Jul 15, 2013
1
0
New understanding of how drugs called PARP inhibitors, which have already shown promise for the treatment of women with familial breast and ovarian cancers linked to BRCA mutations, exert their anticancer effects has led ...
Nov 9, 2012
0
0
(HealthDay)—Newly approved anticancer drugs that do not have a specific molecular target on cancer cells are associated with increased toxicity and the accompanying costs of management, according to research published online ...
Oct 1, 2014
0
0
